A non-interventional, questionnaire-based study of doctors based on their experience with oligomeric formula of whey peptides containing dietary fiber

A non-interventional, questionnaire-based study of doctors based on their experience with oligomeric formula of whey peptides containing dietary fiber - A non-interventional, questionnaire-based study of doctors based on their experience with oligomeric formula of whey peptides containing dietary fiber

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046764

Enrollment

200

Registered

2022-01-28

Start date

2022-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enteral feeding intolerance

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Doctors who meet all of the following criteria at the time of enrollment in this study will be considered subjects of this study. 1) Doctors who understood the study and have given informed consent to participate in the study on the website 2) Doctors with experience in the use of PEPTAMEN PREBIO 3) Doctors who work at a medical institution that has inpatient beds with 24-hour emergency response capability 4) Doctors who is able to input and answer the questionnaire by themselves

Exclusion criteria

Exclusion criteria: No setting

Design outcomes

Primary

Measure	Time frame
1) Background of doctors who responded to the questionnaire of this study (type of hospital, number of beds, department) 2) Background of patients using PEPTAMEN PREBIO (sex, age, basal disease, concomitant drug, main method of nutritional management before using PEPTAMEN PREBIO) 3) Experience of using PEPTAMEN PREBIO 4) Reasons for using PEPTAMEN PREBIO 5) Reasons for discontinuation of use of PEPTAMEN PREBIO 6) Changes in the nutritional status of patients using PEPTAMEN PREBIO 7) Changes in diarrhea symptoms in patients using PEPTAMEN PREBIO 8) Components that contributed to the change of diarrhea after using PEPTAMEN PREBIO 9) Changes in reflux and vomiting symptoms in patients using PEPTAMEN PREBIO 10) Willingness to use PEPTAMEN PREBIO 11) Patients to be considered for use of PEPTAMEN PREBIO	—

Measure

Time frame

1) Background of doctors who responded to the questionnaire of this study (type of hospital, number of beds, department) 2) Background of patients using PEPTAMEN PREBIO (sex, age, basal disease, concomitant drug, main method of nutritional management before using PEPTAMEN PREBIO) 3) Experience of using PEPTAMEN PREBIO 4) Reasons for using PEPTAMEN PREBIO 5) Reasons for discontinuation of use of PEPTAMEN PREBIO 6) Changes in the nutritional status of patients using PEPTAMEN PREBIO 7) Changes in diarrhea symptoms in patients using PEPTAMEN PREBIO 8) Components that contributed to the change of diarrhea after using PEPTAMEN PREBIO 9) Changes in reflux and vomiting symptoms in patients using PEPTAMEN PREBIO 10) Willingness to use PEPTAMEN PREBIO 11) Patients to be considered for use of PEPTAMEN PREBIO

—

Countries

Japan

Contacts

Public ContactHiroki Takano

Nestle Health Science Company, Nestle Japan Ltd. Marketing & Medical Affairs

Hiroki.Takano@jp.nestle.com03-5769-6227

Outcome results